Definium Therapeutics, Inc. DFTX
Definium Therapeutics, Inc. (Nasdaq: DFTX) is a CNS/neurology/psychiatry drug developer. Its lead program, DT120 ODT (lysergide D-tartrate; formerly MM120), is in Phase 3 for Generalized anxiety disorder (also MDD and PTSD). Its next catalyst on record is DT402: Initial Phase 2a data in adult ASD (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: DT402 — Initial Phase 2a data in adult ASD (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| DT120 ODT - Voyage (DT120-300) and Panorama (DT120-301) | Generalized anxiety disorder | small molecule | Phase 3 |
| DT120 ODT - Emerge (DT120-310) | Major depressive disorder | small molecule | Phase 3 |
| DT120 ODT - Ascend (DT120-311) | Major depressive disorder | small molecule | Phase 3 |
| DT120 ODT - Haven | Post-traumatic stress disorder | small molecule | Phase 3 |
| DT402 (R(-)-MDMA; formerly MM402) | Autism spectrum disorder (adults) | small molecule | Phase 2 |
Recent results and decisions
- Sep 14, 2026met Phase 3 Panorama met primary and all key secondary endpoints: HAM-A -9.8 vs -4.7 at Week 12, placebo-adjusted -5.1 (p<0.0001, d=0.64); 50 µg control arm showed smaller effect.
Panorama met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline compared with placebo, as measured by the change in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12.
Filing - Sep 14, 2026n/a FDA Breakthrough Therapy designation now extended to DT120 in MDD (previously GAD only), listed as a September 2026 milestone.
DT120 has received Breakthrough Therapy designation from the FDA for GAD and MDD.
Filing - Aug 12, 2026met Phase 3 Voyage met primary and all key secondary endpoints: HAM-A -11.6 vs -6.2 at Week 12, placebo-adjusted -5.4 (p<0.0001, d=0.81); no suicidality signal.
Voyage met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline compared with placebo, as measured by the change in HAM-A total score at Week 12.
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.